The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 27, 2018

Filed:

Apr. 01, 2014
Applicant:

Roche Glycart Ag, Schlieren, CH;

Inventors:

Peter Bruenker, Hittnau, CH;

Sherif Daouti, Totowa, NJ (US);

Ningping Feng, Richmond Hill, CA;

Claudia Ferrara Koller, Zug, CH;

Guy Georges, Habach, DE;

Sandra Grau-Richards, Birmensdorf, CH;

Ralf Hosse, Cham, CH;

Christian Klein, Bonstetten, CH;

Maximiliane Koenig, Pullach, DE;

Joerg Moelleken, Munich, DE;

Ekkehard Moessner, Kreuzlingen, CH;

Huifeng Niu, Scotch Plains, NJ (US);

Kathryn E. Packman, Newton, MA (US);

Valeria Runza, Penzberg, DE;

Stefan Seeber, Sindelsdorf, DE;

Pablo Umana, Wollerau, CH;

Inja Waldhauer, Urdorf, CH;

Huisheng Wang, Edison, NJ (US);

Barbara Weiser, Sindelsdorf, DE;

Assignee:

ROCHE GLYCART AG, Schlieren, CH;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/40 (2006.01); C07K 16/30 (2006.01); C07K 14/715 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); C07K 16/2875 (2013.01); C07K 16/2878 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/624 (2013.01); C07K 2317/64 (2013.01); C07K 2317/66 (2013.01); C07K 2317/73 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01);
Abstract

The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.


Find Patent Forward Citations

Loading…